Protocol No. 27919: "A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson's Disease with motor fluc

Project: Research project

Project Details

Effective start/end date3/9/103/9/13


  • Quintiles, Inc. (Prot # 27919)
  • EMD Serono, Inc. (Prot # 27919)